Skip to main content
Guhan Pharmaceutical Group Co., Ltd. logo

Guhan Pharmaceutical Group Co., Ltd. — Investor Relations & Filings

Ticker · 000590 ISIN · CNE000000701 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,709 across all filing types
Latest filing 2026-05-18 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 000590

About Guhan Pharmaceutical Group Co., Ltd.

https://www.tuspharma.cn

Guhan Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and sale of traditional Chinese medicine (TCM) and health-related products. The company is widely recognized for its flagship product, Guhan Yangsheng Jing, which is formulated based on ancient health preservation prescriptions discovered in the Mawangdui Han Dynasty Tombs. Its product portfolio includes oral liquids, tablets, and capsules designed to enhance vitality, support kidney function, and promote overall longevity. The organization integrates classical medical theories with modern pharmaceutical manufacturing processes to ensure product efficacy and safety. Beyond its core TCM offerings, the group engages in the production of chemical drugs and health supplements, targeting markets seeking natural wellness solutions. The company emphasizes the preservation of cultural heritage through the modernization of ancient medical wisdom.

Recent filings

Filing Released Lang Actions
关于控股股东之一致行动人增持公司股份进展暨权益变动触及5%整数倍的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public equity change announcement by a controlling shareholder’s concerted actor, reporting that their shareholding has increased by 0.07% to reach exactly 25% of total share capital, thereby crossing a 5% threshold and triggering a mandatory disclosure. This fits the definition of “Major Shareholding Notification (Code: MRQ)” rather than a company share buyback (POS) or other categories.
2026-05-18 Chinese
古汉医药集团股份公司详式权益变动报告书
Major Shareholding Notification Classification · 90% confidence The document is a detailed “权益变动报告书” (Equity Change Report) prepared under China’s Disclosure Guidelines No.15, describing a controlling shareholder’s acquisition of an additional 0.07% stake (increasing their total to 25.00%). It is a shareholder notification of shareholding changes rather than an announcement of new shares or a company buyback. This matches the definition of a Major Shareholding Notification (MRQ).
2026-05-18 Chinese
内部控制审计报告
Regulatory Filings
2026-03-30 Chinese
关于公司2025年度计提资产及信用减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by 古汉医药集团股份公司 regarding the company's 2025年度计提资产及信用减值准备 (provision for asset and credit impairment for the year 2025). It details the amounts and reasons for impairment provisions, the accounting standards applied, and the impact on financial results. The document includes board and audit committee meeting approvals and states that the proposal will be submitted to the shareholders' meeting for approval. The document is 3378 characters long, which is relatively short and reads like an announcement of a financial decision rather than a full financial report. It does not contain full financial statements or comprehensive financial analysis but rather a specific announcement about impairment provisions and related board approvals. This fits best with a Regulatory Filing (RNS) as it is a regulatory announcement about accounting provisions and board decisions, not a full Annual Report (10-K) or Interim Report (IR).
2026-03-30 Chinese
非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Regulatory Filings
2026-03-30 Chinese
董事会关于独立董事独立性情况的专项意见
Board/Management Information Classification · 95% confidence The document is a statement from the board of directors regarding the independence of the company's independent directors, referencing regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange listing rules. It is a specialized opinion on director independence rather than a full report or announcement of a meeting or vote. It does not contain financial data, earnings, or management discussion, nor is it a certification or announcement of a report publication. This fits best under Board/Management Information (MANG), which covers announcements related to board matters and management.
2026-03-30 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.